The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS)

• Published in: BMJ open Vol. 9; no. 3; p. e026797
• Main Authors: Hwang, E Shelley, Hyslop, Terry, Lynch, Thomas, Frank, Elizabeth, Pinto, Donna, Basila, Desiree, Collyar, Deborah, Bennett, Antonia, Kaplan, Celia, Rosenberg, Shoshana, Thompson, Alastair, Weiss, Anna, Partridge, Ann
• Format: Journal Article
• Language: English
• Published: England BMJ Publishing Group LTD 12.03.2019; BMJ Publishing Group
• Subjects: Breast cancer; Breast Neoplasms - prevention & control; Breast Neoplasms - therapy; Cancer surgery; Cancer therapies; Carcinoma in Situ - pathology; Carcinoma in Situ - therapy; Carcinoma, Ductal, Breast - pathology; Carcinoma, Ductal, Breast - therapy; Clinical trials; Combined Modality Therapy; Endocrine therapy; Evidence-based medicine; Female; Humans; Mammography; Mastectomy; Middle Aged; Pain; Patient Outcome Assessment; Patient-Centred Medicine; Patients; Prostate cancer; Risk Assessment; Surveillance; Watchful Waiting; Womens health; United Kingdom > UK; United States > US; clinical trial; ductal carcinoma in situ; breast cancer; non-invasive; active surveillance; surgery

IntroductionDuctal carcinoma in situ (DCIS) is a non-invasive non-obligate precursor of invasive breast cancer. With guideline concordant care (GCC), DCIS outcomes are at least as favourable as some other early stage cancer types such as prostate cancer, for which active surveillance (AS) is a stand...